1. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020. 395(10223): p. 497-506.
2. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020. 395(10223): p. 507-513.
3. Luo, L., et al., The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis. Clin Cardiol, 2020. 43(12): p. 1478-1493.
4. Dong, E., H. Du, and L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases, 2020. 20(5): p. 533-534.
5. Kamboj, M. and K.A. Sepkowitz, Nosocomial infections in patients with cancer. Lancet Oncol, 2009. 10(6): p. 589-97.
6. Li, J.Y., et al., Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res, 2014. 2014: p. 286170.
7. Longbottom, E.R., et al., Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 Pathways. Ann Surg, 2016. 264(2): p. 370-7.
8. Sica, A. and M. Massarotti, Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun, 2017. 85: p. 117-125.
9. Schmidt, T., et al., Influence of physical activity on the immune system in breast cancer patients during chemotherapy. J Cancer Res Clin Oncol, 2018. 144(3): p. 579-586.
10. Hodgson, S.H., et al., What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases, 2021. 21(2): p. e26-e35.
11. Callaway, E., The race for coronavirus vaccines: a graphical guide. Nature, 2020. 580(7805): p. 576-577.
12. Lazarus, J.V., et al., A global survey of potential acceptance of a COVID-19 vaccine. Nat Med, 2021. 27(2): p. 225-228.
13. Wang, J., et al., Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines (Basel), 2020. 8(3).
14. Zhang, Y., X. Luo, and Z.F. Ma, Willingness of the general population to accept and pay for COVID-19 vaccination during the early stages of COVID-19 pandemic: a nationally representative survey in mainland China. Hum Vaccin Immunother, 2021. 17(6): p. 1622-1627.
15. Barriere, J., et al., Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol, 2021. 32(5): p. 673-674.
16. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.
17. Matsen, C.B. and L.A. Neumayer, Breast cancer: a review for the general surgeon. JAMA Surg, 2013. 148(10): p. 971-9.
18. Allemani, C., et al., Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet, 2018. 391(10125): p. 1023-1075.
19. So, A.C.P., et al., COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers (Basel), 2021. 13(14).
20. McDonald, I., et al., Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines, 2021. 6(1): p. 74.
21. Liu, Z.W., et al., PHQ-9 and PHQ-2 for Screening Depression in Chinese Rural Elderly. PLoS One, 2016. 11(3): p. e0151042.
22. Plummer, F., et al., Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry, 2016. 39: p. 24-31.
23. Desai, A., et al., COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Glob Oncol, 2020. 6: p. 557-559.
24. Liang, W., et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol, 2020. 21(3): p. 335-337.
25. Gasparri, M.L., et al., Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). Breast, 2020. 52: p. 110-115.
26. Dietz, J.R., et al., Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat, 2020. 181(3): p. 487-497.
27. Izcovich, A., et al., Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One, 2020. 15(11): p. e0241955.
28. Ribas, A., et al., Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov, 2021. 11(2): p. 233-236.
29. Noor, F.M. and M.M. Islam, Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. J Community Health, 2020. 45(6): p. 1270-1282.
30. Rubin, L.G., et al., 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 2014. 58(3): p. e44-100.
31. Carreira, H., et al., Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. J Natl Cancer Inst, 2018. 110(12): p. 1311-1327.
32. Maass, S.W., et al., The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: A systematic review. Maturitas, 2015. 82(1): p. 100-8.
33. Carreira, H., et al., Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom. PLoS Med, 2021. 18(1): p. e1003504.
34. Anderson, E.J., et al., Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med, 2020. 383(25): p. 2427-2438.
35. Hwang, J.K., et al., COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol, 2021. 14(1): p. 38.